Lorecivivint, an intra-articular potential disease modifying osteoarthritis drug

Osteoarthritis is the most common form of arthritis. Knee OA is associated with pain, activity limitation, and physical disability.

To date, all pharmacologic therapies for knee OA are directed towards symptomatic management.

Lorecivivint (LOR) is a small molecule that modulates the Wnt signal transduction pathways pathway. It is now being investigated as both an analgesic agent and a potential disease-modifying osteoarthritis drug.

Data from a Phase 1 trial showed that LOR was safe and well tolerated. While the Phase 2A trial did not meet its primary endpoint, pre-planned analyses did identify a target population for further evaluation of the potentia…